Lung Cancer, Lung Cancer Metastatic
Conditions
Keywords
lung cancer, lung carcinoma, lung metastases
Brief summary
This research study is being conducted to assess the safety of PDT in subjects with peripherally located malignant tumors in lung parenchyma prior to surgical resection. It will involve up to 10 sites in USA. Participation will last 4 months.
Detailed description
Lung cancer accounts for almost one-third of cancer deaths. Cancer screening strategies have the potential to achieve a 20% reduction in death rates. Newly developed bronchoscopic technologies (such as navigational bronchoscopy) have been shown to enable physicians to safely reach lesions in peripheral regions of the lung and obtain diagnosis. This new technology may now potentially offer bronchoscopic therapeutic interventions, such as photodynamic therapy, to tumors that were previously unreachable due to their peripheral anatomic location. Photodynamic therapy (PDT) uses a combination of a photosensitizing drug (a drug that is activated by light), called porfimer sodium (Photofrin®), and a light from a laser that emits no heat. This technique works to allow the medical doctor to specifically target and destroy abnormal or cancer cells while limiting damage to surrounding healthy tissue. The activation of the drug is done by lightning the abnormal area using a fiber optic device (very fine fiber \[like a fishing line\] that permits light transmission) inserted into a flexible tube with a light, called bronchoscope for the lung. The light activates the porfimer sodium concentrated in the abnormal tissue, leading to its destruction. The purpose of this study is to assess the safety of using photodynamic therapy prior to surgical resection of tumors located in the periphery of the lung.
Interventions
DRUGPorfimer Sodium
Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
DEVICEFiber optic
After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
Sponsors
Concordia Laboratories Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
* Male or female aged 18-79 * Diagnosed with primary or metastatic tumor \< 5 cm located in peripheral lung that can be completely resectable * Candidate for surgical resection * Candidate for bronchoscopy * Tumor is accessible for unrestricted illumination of PDT * Subject is deemed likely to survive for at least 3 months * Non-menopausal/non-sterile female subject of childbearing potential has negative B-HCG (Human chorionic gonadotropin) at time of study entry * Non-menopausal/non-sterile female subject of childbearing potential uses medically acceptable form of birth control * Subject is able and willing to provide written informed consent to participate in the study, which must comply with ICH (International Council for Harmonisation) guidelines & local requirements
Exclusion criteria
* Diagnosis of small cell lung cancer or carcinoid tumors * Primary or metastatic lung tumor located in central lung or near vertebral body * Tumor invades a major blood vessel * Presence of concurrent non-solid malignancy * Tumor previously treated with radiation therapy * Chemotherapy in the last four weeks * Tumor treated with PDT within the last 3 months * Abnormal blood results * Subject with porphyria or hypersensitivity to Photofrin * Coexisting ophthalmic disease likely to required slit-lamp exam within next 90 days * Acute or chronic medical or psychological illness as judged clinical significant to PI to preclude bronchoscopy procedures * female who is breast-feeding or intends to breast-feed during study * subject who participated in another study within last 30 days or intends to participate in another study during this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety: Skin Photosensitivity Events Summaries of Abnormal Findings for Each Subject | 108 days (to 3 months post surgery) | Safety evaluation will include incidence of skin photosensitivity summarized for each subject. |
| Safety: Number of Participants With at Least One Adverse Event | 108 days (to 3 months post surgery) | Safety evaluation will include incidence of all adverse events, including serious and non-serious. The count of how many subjects experienced at least one adverse event. |
| Safety: Physical Examination Summaries of Non-normal Findings for Each Subject | 108 days (to 3 months post surgery) | Safety evaluation will include the physical examinations summary of non-normal findings for each subject. |
| Safety: Vital Sign Summary of Abnormal Findings for Each Subject | 108 days (to 3 months post surgery) | Safety evaluation will include vital sign summary for each subject. Only abnormal counts are included. |
| Safety: Laboratory Tests Summaries of Abnormal Findings for Each Subject | 108 days (to 3 months post surgery) | Safety evaluation will include laboratory tests summarized for each subject with any abnormal lab results considered an AE (adverse event) to be listed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Microscopic Tissue Examination: Number of Participants With Hemorrhage Seen After Surgery | Day 13 to 18 | The Number of Participants with hemorrhage seen during the microscopic tissue examination after surgery |
| Microscopic Tissue Examination: Number of Participants With Necrosis in the Normal Lung After Surgery | Day 13 to 18 | Number of Participants with Necrosis seen in the normal lung after surgery during the Microscopic Tissue Examination |
| Microscopic Tissue Examination: Number of Participants With Pneumonitis in the Normal Lung After Surgery | Day 13 to 18 | The Number of Participants with pneumonitis seen in the normal lung area after surgery following the microscopic tissue examination |
| Microscopic Tissue Examination: Number of Participants With Increased Alveolar Macrophages in the Normal Lung After Surgery | Day 13 to 18 | The number of participants with increased alveolar macrophages post surgery determined in the microscopic tissue examination. |
| Microscopic Tissue Examination: Number of Participants With Atypical/Reactive Type 2 Pneumocytes in the Normal Lung After Surgery | Day 13 to 18 | Number of Participants with Atypical/Reactive Type 2 pneumocytes seen in the normal lung after surgery during the Microscopic Tissue Examination: |
| Microscopic Tissue Examination: Number of Participants With Mucus Plugging/Mucositis in the Normal Lung After Surgery | Day 13 to 18 | Number of Participants with Mucus Plugging/Mucositis seen in the normal lung after surgery during the Microscopic Tissue Examination. |
| Microscopic Tissue Examination: Number of Participants With Interstitial Fibrosis in the Normal Lung After Surgery | Day 13 to 18 | Number of participants with interstitial fibrosis in the normal lung after surgery seen during the Microscopic Tissue Examination |
| Microscopic Tissue Examination: Number of Participants With Large Vessel Damage Indicated by Fibrinoid Necrosis, Thrombus, Vasculitis in the Normal Lung After Surgery | Day 13 to 18 | Number of Participants with Large Vessel Damage indicated by fibrinoid necrosis, thrombus, vasculitis in the normal lung after surgery seen during Microscopic Tissue Examination |
| Macroscopic Tissue Examination | Day 13 to 18 | The mean measurement of tumor size after surgery. The largest diameter seen is measured. |
| Microscopic Tissue Examination: Number of Participants With Organizing Pneumonia Pattern in the Normal Lung After Surgery | Day 13 to 18 | Number of Participants with Organizing pneumonia pattern in the normal lung after surgery seen during Microscopic Tissue Examination |
| ECOG (Eastern Cooperative Oncology Group) Performance Status: Baseline | Baseline (-30 to -1 Days) | Number of Participants with ECOG Performance at Baseline showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead). |
| ECOG Performance Status: Period 1 PDT Day 3 | Day 3 | Number of Participants with ECOG Performance Status at Period 1 PDT Day 3, showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead). |
| ECOG Performance Status: Period II Surgery (Day 13-18) | Day 13 to 18 | Number of Participants with ECOG Performance Status at Period II Surgery (Day 13-18) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead). |
| ECOG Performance Status: Period III Follow-up (Day 20-25) | Day 20 to 25 | Number of Participants with ECOG Performance Status at Period III Follow-up (Day 20-25) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead). |
| ECOG Performance Status: Period III Follow-up (Day 43 -48) | Day 43 to 48 | Number of Participants with ECOG Performance Status at Period III Follow-up (Day 43 -48) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead). |
| ECOG Performance Status: Period III Follow-up (Day 103 - 108) | 108 days (to 3 months post surgery) | Number of Participants with ECOG Performance Status at Period III Follow-up (Day 103 - 108) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead). |
| Microscopic Tissue Examination: Number of Participants With Acute Alveolar Damage in the Normal Lung After Surgery | Day 13 to 18 | Number of Participants with Acute Alveolar damage in the normal lung after surgery seen during the Microscopic Tissue Examination |
| Summary of Microscopic Tissue Examination: Percentage of Participants With Complete Response After Surgery | Day 13 to 18 | The Percentage of Participants with Complete Response in Tumor area (no non-viable/necrotic tumor) after surgery |
| Microscopic Tissue Examination: Percent Tumor Cell Necrosis in Tumor Area After Surgery | Day 13 to 18 | The mean with standard deviation of the percent of tumor cell necrosis in the tumor area after surgery. The tumor itself was examined after it was removed to determine the percent of necrosis seen. |
| Microscopic Tissue Examination: Brisk Inflammatory Reaction After Surgery | Day 13 to 18 | The number of participants showing a brisk inflammatory reaction in the tumor area after surgery. This is determined through a histological examination. Brisk Inflammatory Reaction is defined as lymphocytes that infiltrate diffusely the entire tumor and/or infiltrate across the entire base of the tumor. |
| Microscopic Tissue Examination: Number of Participants With Cavitation in Normal Lung Area After Surgery | Day 13 to 18 | The number of participants with cavitation seen in the normal lung area from the microscopic tissue examination after surgery |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Photofrin and Photodynamic Therapy Open label study. All subjects had a 1-time administration of Photofrin and 1-time use of navigational bronchoscopy-PDT. | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | Photofrin and Photodynamic Therapy |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 3 Participants |
| Age, Categorical Between 18 and 65 years | 7 Participants |
| Peripheral Lung Tumor | 10 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 10 Participants |
| Region of Enrollment United States | 10 participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 10 |
| other Total, other adverse events | 10 / 10 |
| serious Total, serious adverse events | 4 / 10 |
Outcome results
Primary
Safety: Laboratory Tests Summaries of Abnormal Findings for Each Subject
Safety evaluation will include laboratory tests summarized for each subject with any abnormal lab results considered an AE (adverse event) to be listed.
Time frame: 108 days (to 3 months post surgery)
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | Safety: Laboratory Tests Summaries of Abnormal Findings for Each Subject | Albumin (105-04) Period 1: 32 (drop of 10) | 1 Participants |
| Photodynamic Therapy-Photofrin | Safety: Laboratory Tests Summaries of Abnormal Findings for Each Subject | Lab values with no clinically significant change | 9 Participants |
Primary
Safety: Number of Participants With at Least One Adverse Event
Safety evaluation will include incidence of all adverse events, including serious and non-serious. The count of how many subjects experienced at least one adverse event.
Time frame: 108 days (to 3 months post surgery)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Safety: Number of Participants With at Least One Adverse Event | 10 Participants |
Comparison: Adverse events will be listed, coded by MedDRA, by system organ class and preferred term.p-value: <0.05exact Clopper-Pearson binomial method
Primary
Safety: Physical Examination Summaries of Non-normal Findings for Each Subject
Safety evaluation will include the physical examinations summary of non-normal findings for each subject.
Time frame: 108 days (to 3 months post surgery)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | Safety: Physical Examination Summaries of Non-normal Findings for Each Subject | Mouth abnormal at Follow-up (day 103-108) | 1 Participants |
| Photodynamic Therapy-Photofrin | Safety: Physical Examination Summaries of Non-normal Findings for Each Subject | Respiratory abnormal at screening | 1 Participants |
| Photodynamic Therapy-Photofrin | Safety: Physical Examination Summaries of Non-normal Findings for Each Subject | Respiratory abnormal at Follow-up (Day 103-108) | 3 Participants |
Primary
Safety: Skin Photosensitivity Events Summaries of Abnormal Findings for Each Subject
Safety evaluation will include incidence of skin photosensitivity summarized for each subject.
Time frame: 108 days (to 3 months post surgery)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Safety: Skin Photosensitivity Events Summaries of Abnormal Findings for Each Subject | 4 Participants |
Comparison: All adverse event terms are coded using MedDRA Dictionary version 21.1. NCS (Non-Clinical Significant) events were not included in the summary because their CTCAE grade and relationship were not collected. Subjects are counted once within each system organ class and each preferred term. An AE is defined as treatment related if its relationship to the study drug is recorded as reasonable possibility on the CRF (Case Report Form).p-value: <0.05exact Clopper-Pearson binomial method
Primary
Safety: Vital Sign Summary of Abnormal Findings for Each Subject
Safety evaluation will include vital sign summary for each subject. Only abnormal counts are included.
Time frame: 108 days (to 3 months post surgery)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Safety: Vital Sign Summary of Abnormal Findings for Each Subject | 0 Participants |
Secondary
ECOG (Eastern Cooperative Oncology Group) Performance Status: Baseline
Number of Participants with ECOG Performance at Baseline showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).
Time frame: Baseline (-30 to -1 Days)
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | ECOG (Eastern Cooperative Oncology Group) Performance Status: Baseline | ECOG 0 | 7 Participants |
| Photodynamic Therapy-Photofrin | ECOG (Eastern Cooperative Oncology Group) Performance Status: Baseline | ECOG 1 | 3 Participants |
Secondary
ECOG Performance Status: Period 1 PDT Day 3
Number of Participants with ECOG Performance Status at Period 1 PDT Day 3, showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).
Time frame: Day 3
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period 1 PDT Day 3 | ECOG 0 | 6 Participants |
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period 1 PDT Day 3 | ECOG 1 | 4 Participants |
Secondary
ECOG Performance Status: Period III Follow-up (Day 103 - 108)
Number of Participants with ECOG Performance Status at Period III Follow-up (Day 103 - 108) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).
Time frame: 108 days (to 3 months post surgery)
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period III Follow-up (Day 103 - 108) | ECOG 1 | 1 Participants |
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period III Follow-up (Day 103 - 108) | ECOG 0 | 9 Participants |
Secondary
ECOG Performance Status: Period III Follow-up (Day 20-25)
Number of Participants with ECOG Performance Status at Period III Follow-up (Day 20-25) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).
Time frame: Day 20 to 25
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period III Follow-up (Day 20-25) | ECOG 0 | 0 Participants |
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period III Follow-up (Day 20-25) | ECOG 1 | 9 Participants |
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period III Follow-up (Day 20-25) | ECOG 2 | 1 Participants |
Secondary
ECOG Performance Status: Period III Follow-up (Day 43 -48)
Number of Participants with ECOG Performance Status at Period III Follow-up (Day 43 -48) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).
Time frame: Day 43 to 48
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period III Follow-up (Day 43 -48) | ECOG 0 | 7 Participants |
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period III Follow-up (Day 43 -48) | ECOG 1 | 3 Participants |
Secondary
ECOG Performance Status: Period II Surgery (Day 13-18)
Number of Participants with ECOG Performance Status at Period II Surgery (Day 13-18) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).
Time frame: Day 13 to 18
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period II Surgery (Day 13-18) | ECOG 0 | 7 Participants |
| Photodynamic Therapy-Photofrin | ECOG Performance Status: Period II Surgery (Day 13-18) | ECOG 1 | 3 Participants |
Secondary
Macroscopic Tissue Examination
The mean measurement of tumor size after surgery. The largest diameter seen is measured.
Time frame: Day 13 to 18
Population: Photodynamic therapy - Photofrin
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | Macroscopic Tissue Examination | 2.177 CM | Standard Deviation 0.8003 |
Secondary
Microscopic Tissue Examination: Brisk Inflammatory Reaction After Surgery
The number of participants showing a brisk inflammatory reaction in the tumor area after surgery. This is determined through a histological examination. Brisk Inflammatory Reaction is defined as lymphocytes that infiltrate diffusely the entire tumor and/or infiltrate across the entire base of the tumor.
Time frame: Day 13 to 18
Population: The brisk inflammatory reaction percentage seen in the tumor area
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Brisk Inflammatory Reaction After Surgery | 9 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Acute Alveolar Damage in the Normal Lung After Surgery
Number of Participants with Acute Alveolar damage in the normal lung after surgery seen during the Microscopic Tissue Examination
Time frame: Day 13 to 18
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Acute Alveolar Damage in the Normal Lung After Surgery | 0 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Atypical/Reactive Type 2 Pneumocytes in the Normal Lung After Surgery
Number of Participants with Atypical/Reactive Type 2 pneumocytes seen in the normal lung after surgery during the Microscopic Tissue Examination:
Time frame: Day 13 to 18
Population: Number of Participants with Atypical/Reactive Type 2 Pneumocytes in the normal lung after surgery determined during the Microscopic Tissue Examination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Atypical/Reactive Type 2 Pneumocytes in the Normal Lung After Surgery | 10 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Cavitation in Normal Lung Area After Surgery
The number of participants with cavitation seen in the normal lung area from the microscopic tissue examination after surgery
Time frame: Day 13 to 18
Population: Number of participants with cavitation seen in normal lung area
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Cavitation in Normal Lung Area After Surgery | 1 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Hemorrhage Seen After Surgery
The Number of Participants with hemorrhage seen during the microscopic tissue examination after surgery
Time frame: Day 13 to 18
Population: Number of Participants with Hemorrhage seen in normal lung area after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Hemorrhage Seen After Surgery | 6 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Increased Alveolar Macrophages in the Normal Lung After Surgery
The number of participants with increased alveolar macrophages post surgery determined in the microscopic tissue examination.
Time frame: Day 13 to 18
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Increased Alveolar Macrophages in the Normal Lung After Surgery | 10 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Interstitial Fibrosis in the Normal Lung After Surgery
Number of participants with interstitial fibrosis in the normal lung after surgery seen during the Microscopic Tissue Examination
Time frame: Day 13 to 18
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Interstitial Fibrosis in the Normal Lung After Surgery | Mild | 0 Participants |
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Interstitial Fibrosis in the Normal Lung After Surgery | Moderate | 1 Participants |
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Interstitial Fibrosis in the Normal Lung After Surgery | Severe | 0 Participants |
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Interstitial Fibrosis in the Normal Lung After Surgery | None | 9 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Large Vessel Damage Indicated by Fibrinoid Necrosis, Thrombus, Vasculitis in the Normal Lung After Surgery
Number of Participants with Large Vessel Damage indicated by fibrinoid necrosis, thrombus, vasculitis in the normal lung after surgery seen during Microscopic Tissue Examination
Time frame: Day 13 to 18
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Large Vessel Damage Indicated by Fibrinoid Necrosis, Thrombus, Vasculitis in the Normal Lung After Surgery | 1 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Mucus Plugging/Mucositis in the Normal Lung After Surgery
Number of Participants with Mucus Plugging/Mucositis seen in the normal lung after surgery during the Microscopic Tissue Examination.
Time frame: Day 13 to 18
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Mucus Plugging/Mucositis in the Normal Lung After Surgery | 0 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Necrosis in the Normal Lung After Surgery
Number of Participants with Necrosis seen in the normal lung after surgery during the Microscopic Tissue Examination
Time frame: Day 13 to 18
Population: Number of Participants with Necrosis in the normal lung after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Necrosis in the Normal Lung After Surgery | 3 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Organizing Pneumonia Pattern in the Normal Lung After Surgery
Number of Participants with Organizing pneumonia pattern in the normal lung after surgery seen during Microscopic Tissue Examination
Time frame: Day 13 to 18
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Organizing Pneumonia Pattern in the Normal Lung After Surgery | 7 Participants |
Secondary
Microscopic Tissue Examination: Number of Participants With Pneumonitis in the Normal Lung After Surgery
The Number of Participants with pneumonitis seen in the normal lung area after surgery following the microscopic tissue examination
Time frame: Day 13 to 18
Population: Microscopic Tissue Examination: Pneumonitis in the normal lung after surgery. Looked at Number of Participants with pneumonitis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Number of Participants With Pneumonitis in the Normal Lung After Surgery | 2 Participants |
Secondary
Microscopic Tissue Examination: Percent Tumor Cell Necrosis in Tumor Area After Surgery
The mean with standard deviation of the percent of tumor cell necrosis in the tumor area after surgery. The tumor itself was examined after it was removed to determine the percent of necrosis seen.
Time frame: Day 13 to 18
Population: All subjects were examined for percent tumor cell necrosis in the tumor area
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Photodynamic Therapy-Photofrin | Microscopic Tissue Examination: Percent Tumor Cell Necrosis in Tumor Area After Surgery | 22.0 Percent of tumor | Standard Deviation 17.67 |
Secondary
Summary of Microscopic Tissue Examination: Percentage of Participants With Complete Response After Surgery
The Percentage of Participants with Complete Response in Tumor area (no non-viable/necrotic tumor) after surgery
Time frame: Day 13 to 18
Population: Look at complete response in the tumor area
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Photodynamic Therapy-Photofrin | Summary of Microscopic Tissue Examination: Percentage of Participants With Complete Response After Surgery | 20 percentage of participants |